Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -30,836 | -47,047 | -41,066 | -38,776 | -30,527 |
| Depreciation Amortization | 53 | 37 | 33 | 32 | 41 |
| Other Working Capital | 609 | 2,284 | 4,678 | 4,968 | 3,957 |
| Other Operating Activity | 6,299 | 2,959 | 3,390 | 2,720 | 2,221 |
| Operating Cash Flow | $-23,875 | $-41,767 | $-32,965 | $-31,056 | $-24,308 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 21,000 | 30,000 | 30,000 | 10,000 | 30,000 |
| Common Stock Issued | 5,475 | 1,227 | 10,033 | N/A | 6,814 |
| Financing Cash Flow | $26,475 | $31,227 | $40,033 | $10,000 | $36,814 |
| Beginning Cash Position | 15,120 | 25,660 | 18,592 | 39,648 | 27,142 |
| End Cash Position | 17,720 | 15,120 | 25,660 | 18,592 | 39,648 |
| Net Cash Flow | $2,600 | $-10,540 | $7,068 | $-21,056 | $12,506 |
| Free Cash Flow | |||||
| Operating Cash Flow | -23,875 | -41,767 | -32,965 | -31,056 | -24,308 |
| Free Cash Flow | -23,875 | -41,767 | -32,965 | -31,056 | -24,308 |